BlueRock Therapeutics
- Active openings
- 3
- US-based roles
- 3
- Remote-friendly
- 0
- Last updated
- 2026-09-30
What BlueRock Therapeutics is hiring for
Open positions
3 active- Research Associate I, Process DevelopmentNYSep 30
- Director, Patient AdvocacyCambridge, MASep 29
- Senior Director/Vice President, Program Team Leader, Neurology and Pipeline AssetsCambridge, MASep 26
About BlueRock Therapeutics
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA
FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001
BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases